Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-25
2007-12-25
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S366000, C514S475000, C514S183000
Reexamination Certificate
active
10091061
ABSTRACT:
Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
REFERENCES:
patent: 5728687 (1998-03-01), Bissery
patent: 6162804 (2000-12-01), Bilodeau et al.
patent: 6194181 (2001-02-01), Hofmann et al.
patent: 6204388 (2001-03-01), Danishefsky et al.
patent: 6211412 (2001-04-01), Georg et al.
patent: 6262094 (2001-07-01), Hoefle et al.
patent: 6365749 (2002-04-01), Kim et al.
patent: 6380395 (2002-04-01), Vite et al.
patent: 6399638 (2002-06-01), Vite et al.
patent: 6441026 (2002-08-01), Bissery
patent: 6441186 (2002-08-01), Nicolaou et al.
patent: 6462017 (2002-10-01), Rudolph et al.
patent: 6498257 (2002-12-01), Vite et al.
patent: 6537988 (2003-03-01), Lee
patent: 6548531 (2003-04-01), Breimer et al.
patent: 6576651 (2003-06-01), Bandyopadhyay et al.
patent: 6586428 (2003-07-01), Geroni et al.
patent: 6593115 (2003-07-01), Vite et al.
patent: 6605599 (2003-08-01), Vite et al.
patent: 6670384 (2003-12-01), Bandyopadhyay et al.
patent: 6686380 (2004-02-01), Lee
patent: 6689802 (2004-02-01), DiMarco et al.
patent: 6727276 (2004-04-01), Lee
patent: 6780620 (2004-08-01), Li et al.
patent: 6831090 (2004-12-01), Vite et al.
patent: 6867305 (2005-03-01), Danishefsky et al.
patent: 2002/0177548 (2002-11-01), Schwendner et al.
patent: 2002/0198216 (2002-12-01), Njoroge et al.
patent: 2003/0191162 (2003-10-01), Langecker et al.
patent: 2004/0023925 (2004-02-01), Chang et al.
patent: 4 138 042 (1993-05-01), None
patent: 195 42 986.9 (1997-05-01), None
patent: 196 39 456.2 (1997-05-01), None
patent: 196 36 343.8 (1998-03-01), None
patent: 196 45 361.5 (1998-04-01), None
patent: 196 45 362.3 (1998-04-01), None
patent: 196 47 580.5 (1998-05-01), None
patent: 197 01 758 (1998-07-01), None
patent: 197 07 505.3 (1998-09-01), None
patent: 197 13 970 (1998-10-01), None
patent: 197 20 312 (1998-11-01), None
patent: 198 21 954 (1998-11-01), None
patent: 197 26 627 (1998-12-01), None
patent: 0 879 605 (1998-11-01), None
patent: WO 93/10121 (1993-05-01), None
patent: WO 97/19086 (1997-05-01), None
patent: WO 98/08849 (1998-03-01), None
patent: WO 98/22461 (1998-05-01), None
patent: WO 98/24427 (1998-06-01), None
patent: WO 98/25929 (1998-06-01), None
patent: WO 98/38192 (1998-09-01), None
patent: WO 98/47891 (1998-10-01), None
patent: 99/02514 (1999-01-01), None
patent: WO 99/01124 (1999-01-01), None
patent: WO 99/03848 (1999-01-01), None
patent: WO 99/07692 (1999-02-01), None
patent: WO 99/27890 (1999-06-01), None
patent: WO 99/39694 (1999-08-01), None
patent: WO 99/42602 (1999-08-01), None
patent: WO 99/43320 (1999-09-01), None
patent: WO 99/43653 (1999-09-01), None
patent: WO 99/54319 (1999-10-01), None
patent: WO 99/67252 (1999-12-01), None
patent: WO 00/00485 (2000-01-01), None
patent: WO 00/31247 (2000-06-01), None
patent: WO 00/37473 (2000-06-01), None
patent: WO 00/38519 (2000-07-01), None
patent: WO 00/38730 (2000-07-01), None
patent: WO 00/49021 (2000-08-01), None
patent: WO 00/66589 (2000-11-01), None
patent: WO 01/07082 (2001-02-01), None
patent: WO 01/34133 (2001-05-01), None
patent: WO 01/49287 (2001-07-01), None
patent: WO 01/82949 (2001-11-01), None
patent: WO 02/39958 (2002-05-01), None
patent: WO02/067941 (2002-06-01), None
patent: WO02/067941 (2002-09-01), None
patent: WO02/074042 (2002-09-01), None
patent: WO 02/089824 (2002-11-01), None
patent: WO02/057217 (2003-07-01), None
patent: WO03/057217 (2003-07-01), None
Saeki et al., Mechanism and Possible Biochemical Modulation of Capecitabine (Xeloda), a Newly Generated Oral Fluoropyrimidine, Gan To Kagaku Ryoho, Mar. 26, 1999, 26(4):447-55, abstract.
Budavari et al. The Merck Index, (12th ED), 1996, MISC-10, THER-13.
Miwa et al. European Journal of Cancer (1998), 34(8), 1274-1281.
Trisha Gura's article in Science, Nov. 1997, vol. 278, p. 1041-1042.
Altmann, K.-H. et al., “Epothilones and related structures—a new class of microtubule inhibitors with potent in vivo antitumor activity”, Biochimica et Biophysica Acta, vol. 1470, pp. M79-M91 (2000).
Baker, S.D., “Drug Interactions with the Taxanes”, Pharmacotherapy, vol. 17, No. 5, Pt. 2, pp. 126S-132S (1997).
Balog, A. et al., “Total Synthesis of (—).Epothilone A”, Angew. Chem. Int. Ed. Engl., vol. 35, No. 23.24m oo, 2801-2803 (1996).
Bertinato, P. et al., “Studies toward a Synthesis of Epothilone A: Stereocontrolled Assembly of the Acyl Region and Models for Macrocyclization”, J. Org. Chem. vol. 61, No. 23, pp. 8000-8001 (1996).
Bertini, F. et al., “Alkenes from Epoxides by Reductive Elimination with Magnesium Bromide-Magnesium Amalgam”, Chemical Communications, p. 144 (1970).
Bissery, M.C. et al., “Preclinical In Vivo Activity of Docetaxel-Containing Combinations”, Proceedings of ASCO, vol. 14, No. 1599, p. 489 (1995).
Bissery, M.-C. et al., “Preclinical Profile of Docetaxel (Taxotere): Efficacy as a Single Agent and in Combination”, Seminars in Oncology, vol. 22, No. 6, Suppl. 13, pp. 3-16 (1995).
Bollag, D.M., “Epothilones: novel microtubule-stabilising agents”, Exp. Opin. Invest. Drugs., vol. 6, No. 7, pp. 867-873 (1997).
Bollag, D.M. et al., “Epothilone, a new structural class of microtubule stabilizer”, Proceedings of the American Association for Cancer Research, Abstract, vol. 36, No. 2711, p. 454 (1995).
Bollag, D.M. et al., “Epothilones, a New Class of Microtubule-stabilizing Agents with a Taxol-like Mechanism of Action”, Cancer Research, vol. 55, pp. 2325-2333 (1995).
Borman, S., “Epothilone Epiphany: Total Syntheses”, Chemical & Engineering News, vol. 74, No. 52, pp. 24-26 (1996).
Chemical & Engineering News, “First total synthesis of epothilone B”, vol. 75, No. 13, p. 23, (1997).
Chemical & Engineering News, “Solid-phase epothilone synthesis used to create analog library”, vol. 75, No. 20, p. 33 (1997).
Claus, E. et al., “Synthesis of the C1-C9 Segment of Epothilons”, Tetrahedron Letters, vol. 38, No. 8, pp. 1359-1362 (1997).
De Brabander, J. et al., “Towards a Synthesis of Epothilone A: Rapid Assembly of the C1-C6 and C7-C12 Fragments”, Synlett, vol. 7, pp. 824-826 (1997).
Fujisawa, T. et al., “Deoxygenation of Epoxides to Olefins with FeCl3—n-BuLi System”, Chemistry Letters, pp. 883-886 (1974).
Fujiwara, Y. et al., “Reductive Coupling of Carbonyl Compounds to Olefins by Tungsten Hexachloride-Lithium Aluminum Hydride and Some Tungsten and Molybdenum Carbonyls”, J. Org. Chem., vol. 43, No. 12, pp. 2477-2479 (1978).
Gabriel, T. et al., “The Chromium-Reformatsky Reaction: Asymmetric Synthesis of the Aldol Fragment of the Cytotoxic Epothilons from 3-(2-Bromacyl)-2-oxazolidinones”, Tetrahedron Letters, vol. 38, No. 8, pp. 1363-1366 (1997).
Gerth, K. et al., “Epothilons A and B: Antifungal and Cytotoxic Compounds fromSorangium cellulosum(Myxobacteria): Production, Physico-chemical and Biological Properties”, The Journal of Antibiotics, vol. 49, No. 6, pp. 560-563 (1996).
Gladysz, J.A. et al., “Deoxygenation of Epoxides by Metal Atom Cocondensation”, J. Org. Chem., vol. 41, No. 22, pp. 3647-3648 (1976).
Höfle, G. et al., “Epothilone A and B—Novel 16-Membered Macrolides with Cytotoxic Activity: Isloation, Crystal Structure, and Conformation in Solution”, Angew. Chem. Int. Ed. Engl., vol. 35, No. 13/14 pp. 1567-1569 (1996).
Höfle, G. et al., “N-Oxidation of Epothilone A-C and O-Acyl Rearrangement to C-19- and C-21- Substituted Epothilones”, Angew. Chem. Int. Ed., vol. 38, No. 13/14, pp. 1971-1974 (1999).
Holmes, F.A., “Paclitaxel Combination Therapy in the Treatment of Metastatic Breast Cancer”, Seminars in Oncology, vol. 23, No. 5, Suppl. 12, pp. 29-39 (1996).
Hortobagyi, G.N. et al., “Paclitaxel-Containing Combination Chemotherapy for Metastatic Breast Cancer”, Seminars in Oncology, vol. 23, No. 1, Suppl. 1, pp. 53-57 (1996).
Inokuchi, T. e
Bristol-Myers Squibb Co.
Chong Yong S.
Padmanabhan Sreeni
Winslow Anastasia P.
LandOfFree
Combination of epothilone analogs and chemotherapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of epothilone analogs and chemotherapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of epothilone analogs and chemotherapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3885866